Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00083070 · ClinicalTrials.gov registry record · Phase 1
Temozolomide in Treating Young Patients With Refractory or Recurrent Leukemia
A Phase 1 study, sponsored by Children's Oncology Group.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT00083070 is a Phase 1 study that has completed, run by Children's Oncology Group. The registered enrollment target is 16 participants.
The verdict
NCT00083070, a Phase 1 study, has completed, sponsored by Children's Oncology Group.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects and best dose of temozolomide in treating young patients with refractory or recurrent leukemia.
Interventions
- DRUG temozolomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2004-03 |
| Est. Completion | 2008-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00083070
The ClinicalTrials.gov registry entry for NCT00083070 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Oncology Group, which has 342 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which temozolomide is the first listed.
NCT00083070 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00083070 about?
NCT00083070 is a clinical study titled "Temozolomide in Treating Young Patients With Refractory or Recurrent Leukemia". RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects and best dose of temozolomide in treating young patients with refractory or recurrent leukemia...
What is the current status of trial NCT00083070?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2004-03. Estimated completion is 2008-06.
What interventions are being tested in trial NCT00083070?
The interventions under investigation include: temozolomide (DRUG).
Who is sponsoring clinical trial NCT00083070?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.